The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

A recent study in the field of neurobiology, presented in Science China Life Sciences, uncovers a pivotal role for the ...

Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive ...

A collaborative study in neuroscience, spearheaded by a research team of the Hong Kong University of Science and Technology ...

Robert W. Baird started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a research note issued to ...

Dr. Iweka discovered that PLPPR1 impedes the inhibitory activity of CSPGs and other inhibitory molecules such as lysophosphatidic acid, by modulating Rho-GTPases during CNS injury. During her ...

PubMed PMID: 17617061. Khurana S, Tomar A, George SP, Wang Y, Siddiqui MR, Guo H, Tigyi G, Mathew S. Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the ...

Lipin1 is an enzyme that, when inhibited in retinal ganglion cells, promotes nerve repair by shifting lipid synthesis from storage lipids to phospholipids, while also producing signaling lipids like ...